Wall Street Zen upgrades Dr Reddy to Hold: what it means for Dr Reddy stock

Published on 10/20/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy disclosed three FDA observations on October 14, 2026. Q2 results arrive October 23, and the consensus rating for Dr Reddy stock is Hold.

Regulatory update before results

Dr. Reddy's Laboratories disclosed three FDA observations on October 14, 2026.
Q1 FY27 revenue was INR 80.71 billion and net income was INR 4.35 billion.
Dr. Reddy's will release second-quarter results on October 23, 2026.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Dr. Reddy's Laboratories (ISIN INE089A01023) was upgraded from Sell to Hold by Wall Street Zen on October 17, 2026, according to MarketBeat. The move gives the stock a more cautious backdrop ahead of its scheduled second-quarter results.

What the observations mean

Business Today reported on October 15, 2026, that the United States Food and Drug Administration issued three Form 483 observations after an October 8 to October 9 inspection at the FTO-9 facility in Visakhapatnam. Dr. Reddy's said it would address the observations within the stipulated timeline.

The regulatory item matters because the company is entering a results window after a difficult first quarter. Q1 FY27 revenue was INR 80.71 billion for the period ended June 30, 2026, while consolidated net income was INR 4.35 billion, according to Yahoo Finance. Separate coverage put the year-over-year declines at 5.60 percent for revenue and 69.00 percent for profit.

Three dates frame the stock

On September 29, 2026, Citi raised its target from INR 1,040 to INR 1,450 and upgraded the shares to Buy, as reported by ET Now. On October 14, 2026, the company disclosed three FDA observations at FTO-9, and on October 17, 2026, Wall Street Zen moved its rating from Sell to Hold.

When are the next results

StockTitan reported that Dr. Reddy's will release results for the quarter and six months ended September 30, 2026, on October 23, 2026. The earnings call is scheduled for 10:00 a.m. ET on the same date.

Regulatory detail meets earnings risk

For investors, the key test is whether the second-quarter figures show recovery after the Q1 decline while the company addresses the FTO-9 observations. The upcoming report should also clarify how management views product launches, generic pricing and margin pressure.

Indian listing remains the reference

Dr. Reddy's Laboratories is headquartered in Hyderabad and operates across generic medicines, active pharmaceutical ingredients, biosimilars and consumer health products. Its shares are listed on the New York Stock Exchange under ticker RDY, as identified in the company's October 7, 2026 filing.